Horama is strengthening its teams with the arrival of three new experts

Jean-Yves Deslandes – Chief Medical Officer

Download the free guide
Boost your gains

Nicolas Delaunay – Responsible for CMC
Jerome Vailland – Chief Financial Officer

Paris, 29 June 2017 – Horama (www.horama.fr), a French biotechnology company based in Paris and specialized in gene therapy for the treatment of rare genetic diseases in ophthalmology, today announces the appointment of three new experts : Jean-Yves Deslandes, Nicolas Delaunay, and Jerome Vailland.

The company was created in march 2014, the ambition of which is to treat retinopathies hereditary – diseases ophthalmic orphan – complete its management team with three new hires.

“We are thrilled to announce today the recruitment of these three talents to key positions within Horama. Their expertise and their longevity in their respective fields of competence and their human qualities allow us to assert that they will contribute significantly to the development of the activity of Horama in its objective treatment of the rare genetic diseases of the eye, ” said Christine Placet, ceo and President of Horama.

Jean-Yves Deslandes, Chief Medical Officer


Recruited within Horama in April, Jean-Yves Deslandes has an international experience of over 25 years in the pharmaceutical industry in Europe and the United States, with significant experience in ophthalmology and gene therapy of the eye. He notably held the position of project Manager-clinical Retina at Alcon/Novartis, Director of Clinical Research at Sanofi-Fovea and that of Director of the department of Clinical Research at Allergan Europe. He holds a doctorate of medicine from the University of Paris VII.

Nicolas Delaunay, Head of CMC

Arrived at Horama in November 2016, Nicolas Delaunay has expertise in project management of pharmaceutical development for drug and gene therapy. During 13 years spent at Généthon, Nicolas has participated in the implementation of the quality system pharmaceutical and then he held the position of Quality Manager Product as a Pharmacist Delegate. He was in charge of the certification of the batches of investigational medicinal products for gene therapy. He was then recruited within the MSNA as a clinical evaluator in ophthalmology. Nicolas Delaunay holds a state diploma of doctor of pharmacy (FACULTY of Pharmacy of Paris XI) and is also holder of two Masters degrees : one in Public Health specializing in Health Economics and the other in Control and Quality Assurance of gene therapy products and cell phone.

Jerome Vailland, Chief Financial Officer

The position of CFO of Horama since November of 2016, Jerome Vailland has 15 years of experience in auditing, management and transactions. Having started out as a management controller within the group, Bouygues Telecom, he then became a Senior Manager at Ernst & Young for 11 years. It carries on activities of office of the commissioner of accounts, consulting and transaction support during ipos, mainly in the life sciences, in parallel with managerial responsibilities (leading teams, business development, recruitment, etc). Jerome Vailland is a graduate of Audencia-Nantes, specializing in audit-management control.

About Horama

Horama is a biopharmaceutical company in clinical stage, which develops treatments of gene therapy based on vectors derived from a recombinant adeno-associated virus (rAAV) and targeting of rare diseases of the retina. The company’s portfolio includes two products that will go into clinical in the next few months. Horama was created in 2014, at the initiative of the team of academic researchers who has conducted as early as 2011, one of the first clinical trials of gene therapy applied to ophthalmology. These researchers are the founders of Horama (Philippe Moullier, Christian Hamel and Vasiliki Kalatzis INSERM, Michel Weber and Guylène Le Meur CHU of Nantes) with complementary skills recognised on the international stage.

For more information : www.horama.fr

Download the free guide
Boost your gains

Like this post? Please share to your friends:
Leave a Reply